About Us
Indapta is a biotechnology company harnessing the natural power of the immune system to fight hematologic and solid cancers with its universal natural killer (NK) cell platform derived from healthy donors. The company’s allogeneic platform is based on a subset of NK cells that are deficient in the FceR1g protein, and are called g-NK cells (g minus NK cells). These cells are particularly potent at killing cancer cells when combined with monoclonal antibodies. Indapta is working to bring this off-the-shelf cellular therapy to cancer patients to address the limitations of currently available immunotherapies. Indapta is based in Houston, TX, and Seattle, WA.
G-NK cell therapy is an off-the-shelf solution, eliminating the need for a patient-specific therapy.
G-NK cell therapy is combined with FDA-approved tumor-targeting antibodies.
Leadership
Robert Sikorski, MD
Acting Chief Medical Officer
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?
Guy DiPierro
Chief Operating Officer and Co-Founder
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?
Austin Bigley, PH.D.
VP of Research
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?
Nina Shah, M.D.
Clinical Professor of Medicine, University of California, San Francisco
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?
Science And Platform
Cancer is the leading cause of death worldwide. Current therapies are suboptimal, frequently ineffective and often cause significant side effects.
Immunotherapies are a formidable new mechanism to fight cancer. Designed to boost the immune response, immunotherapies such as G-NK therapy were developed to address the limitations of currently available autologous T-cell therapies.
Indapta is developing a universal, allogeneic NK cell therapy designed to substantially improve the cytotoxicity of antibody therapy in cancer. Engineered by nature to fight cancer and infectious diseases, Indapta’s NK cell platform is based on a naturally occurring subset of natural killer cells known as g-NK cells that that have undergone epigenetic changes including the down-modulation of the FceR1γ chain. Compared to conventional NK cells, g-NK cells demonstrate increased cytokine secretion, higher levels of cytolytic enzymes, a more favorable metabolic profile, increased persistence, and markedly higher antibody dependent cell mediated cytotoxicity (ADCC).
Indapta has demonstrate robust anti-cancer effects in preclinical models of cancer using g-NK cells in combination with rituximab in NHL, and in combination with daratumumab in multiple myeloma. These effects are markedly superior to conventional NK cells in combination with monoclonal antibodies.
Indapta has developed a proprietary process to expand g-NK cells that yields a highly potent product without the need for artificial genetic engineering. The company’s first-in-human Phase 1 trial will treat relapsed/refractory non-Hodgkin’s lymphoma and multiple myeloma patients with g-NK cells in combination with rituximab and daratumumab, respectively.
Recent News
January 17
2023
Indapta Therapeutics Names Moya Daniels, Senior Vice President of Regulatory and Clinical Operations
August 10
2022
“Indapta Therapeutics CEO, Mark Frohlich, is interviewed by WuXi AppTec on “Delivering on the Promise of New Modalities.”
February 11
2022
Indapta Therapeutics CEO, Mark Frohlich, interviewed by the San Francisco Business Times
February 10
2022
Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance Development of G-NK Cell Therapy to Treat Multiple Types of Cancer
August 10
2021
Indapta Therapeutics Announces New Preclinical Data Demonstrating Proprietary G-NK Cells Enhance Efficacy of Monoclonal Antibodies in Multiple Myeloma
February 03
2021
Indapta Therapeutics Announces Key Management Team Appointments to Advance into Clinical Trials in 2021
October 28
2020
Multiple Myeloma Research Foundation (MMRF) and Indapta Therapeutics Announce Investment to Advance Clinical Development of Natural Killer Cell Therapy
August 29
2020
Indapta Therapeutics Appoints Dov Goldstein, M.D., Chief Financial and Business Officer
January 10
2020
Indapta Therapeutics and Lonza Announce Strategic Partnership to Advance a Next-generation, Off-the-shelf, Allogeneic Immuno-oncology Therapy
Corporate Presentation
SLIDE 1PUBLICATIONS
Indapta has demonstrated robust anti-cancer effects in preclinical models of cancer using g-NK cells in combination with rituximab in NHL, and in combination with daratumumab in multiple myeloma. These effects are markedly superior to conventional NK cells in combination with monoclonal antibodies.